Effects of stress reduction on cardiovascular risk factors in type 2 diabetes patients with early kidney disease - Results of a randomized controlled trial (HEIDIS)

Experimental and Clinical Endocrinology and Diabetes

Volumn 122, Issue 6, 2014, Pages 341-349

  Kopf, S ^a   Oikonomou, D ^a   Hartmann, M ^a   Feier, F ^a   Faude Lang, V ^a,b   Morcos, M ^a,c   Haring H U ^d   Herzog, W ^a   Bierhaus, A ^a   Humpert, P M ^a,c   Nawroth, P P ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF HAMBURG   (Germany)

^c Stoffwechselzentrum Rhein Pfalz   (Germany)

^d UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

cardiovascular risk; diabetic kidney disease; MBSR; psychosocial stress; type 2 diabetes

Indexed keywords

ALBUMIN; CREATININE;

ADULT; ALBUMIN CREATININE RATIO; ARTERIAL WALL THICKNESS; ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMPUTER ANALYSIS; CONTROLLED STUDY; DIABETIC NEPHROPATHY; FEMALE; FOLLOW UP; HUMAN; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; MINDFULNESS BASED STRESS REDUCTION TRAINING; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOSOCIAL CARE; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL; RENAL SYSTEM PARAMETERS; SYSTOLIC BLOOD PRESSURE; URINARY ALBUMIN EXCRETION; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; MENTAL STRESS; MIDDLE AGED; PSYCHOLOGY; RISK FACTOR;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; STRESS, PSYCHOLOGICAL;

EID: 84902788188     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/s-0034-1372583     Document Type: Article

References (53)

1. Yusuf S., Hawken S., Ounpuu S. et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet: 2004; 364 937 952 (Pubitemid 39208455)
2. Berry J. D., Dyer A., Cai X. et al. Lifetime risks of cardiovascular disease. N Engl J Med: 2012; 366 321 329
3. Haffner S. M., Lehto S., Ronnemaa T. et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med: 1998; 339 229 234 (Pubitemid 28350165)
4. Yang Z., Xing X., Xiao J. et al. Prevalence of cardiovascular disease and risk factors in the Chinese population with impaired glucose regulation: the 2007-2008 China national diabetes and metabolic disorders study. Exp Clin Endocrinol Diabetes: 2013; 121 372 374
5. Patel A., MacMahon S., Chalmers J. et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med: 2008; 358 2560 2572 (Pubitemid 351831357)
6. Gerstein H. C., Miller M. E., Byington R. P. et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med: 2008; 358 2545 2559 (Pubitemid 351831356)
7. Duckworth W., Abraira C., Moritz T. et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med: 2009; 360 129 139
8. Nawroth P. P., Rudofsky G., Humpert P. Have we understood diabetes? New tasks for diagnosis and therapy. Exp Clin Endocrinol Diabetes: 2010; 118 1 3
9. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet: 1998; 352 854 865
10. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet: 2000; 355 253 259
11. Colhoun H. M., Betteridge D. J., Durrington P. N. et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet: 2004; 364 685 696 (Pubitemid 39140624)
12. Hamer M., Molloy G. J., Stamatakis E. Psychological distress as a risk factor for cardiovascular events: pathophysiological and behavioral mechanisms. J Am Coll Cardiol: 2008; 52 2156 2162
13. Yang W., Lu J., Weng J. et al. Prevalence of diabetes among men and women in China. N Engl J Med: 2010; 362 1090 1101
14. Blumenthal J. A., Sherwood A., Babyak M. A. et al. Effects of exercise and stress management training on markers of cardiovascular risk in patients with ischemic heart disease: a randomized controlled trial. JAMA: 2005; 293 1626 1634 (Pubitemid 40471793)
15. Denollet J., Brutsaert D. L. Reducing emotional distress improves prognosis in coronary heart disease: 9-year mortality in a clinical trial of rehabilitation. Circulation: 2001; 104 2018 2023 (Pubitemid 33027040)
16. McEwen B. S. Allostasis and allostatic load: implications for neuropsychopharmacology. Neuropsychopharmacology: 2000; 22 108 124 (Pubitemid 30016013)
17. Thayer J. F., Yamamoto S. S., Brosschot J. F. The relationship of autonomic imbalance, heart rate variability and cardiovascular disease risk factors. Int J Cardiol: 2010; 141 122 131
18. Rozanski A., Blumenthal J. A., Kaplan J. Impact of psychological factors on the pathogenesis of cardiovascular disease and implications for therapy. Circulation: 1999; 99 2192 2217 (Pubitemid 29196806)
19. Adams D. O. Molecular biology of macrophage activation: a pathway whereby psychosocial factors can potentially affect health. Psychosom Med: 1994; 56 316 327 (Pubitemid 24233891)
20. Bierhaus A., Wolf J., Andrassy M. et al. A mechanism converting psychosocial stress into mononuclear cell activation. Proc Natl Acad Sci USA: 2003; 100 1920 1925 (Pubitemid 36254549)
21. Bierhaus A., Humpert P. M., Nawroth P. P. Linking stress to inflammation. Anesthesiol Clin: 2006; 24 325 340
22. Danesh J., Wheeler J. G., Hirschfield G. M. et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med: 2004; 350 1387 1397 (Pubitemid 38419992)
23. Surwit R. S., van Tilburg M. A., Zucker N. et al. Stress management improves long-term glycemic control in type 2 diabetes. Diabetes Care: 2002; 25 30 34 (Pubitemid 41070779)
24. Rubin R. R., Peyrot M. Psychosocial problems and interventions in diabetes. A review of the literature. Diabetes Care: 1992; 15 1640 1657
25. Hartmann M., Kopf S., Kircher C. et al. Sustained Effects of a Mindfulness-Based Stress-Reduction Intervention in Type 2 Diabetic Patients: Design and first results of a randomized controlled trial (The Heidelberger Diabetes and Stress-Study). Diabetes Care: 2012; 35 945 947
26. Ninomiya T., Perkovic V., de Galan B. E. et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol: 2009; 20 1813 1821
27. Eurich D. T., Majumdar S. R., Tsuyuki R. T. et al. Reduced mortality associated with the use of ACE inhibitors in patients with type 2 diabetes. Diabetes Care: 2004; 27 1330 1334 (Pubitemid 38679979)
28. Kabat-Zinn J. Full Catastrophe Living: Using the Wisdom of Your Body and Mind to Face Stress, Pain, and Illness: How to Cope with Stress, Pain and Illness Using Mindfulness Meditation. 1990; Delta
29. Ludwig D. S., Kabat-Zinn J. Mindfulness in medicine. JAMA: 2008; 300 1350 1352
30. Faude-Lang V., Hartmann M., Schmidt E. M. et al. Acceptance- and mindfulness-based group intervention in advanced type 2 diabetes patients: therapeutic concept and practical experiences. Psychother Psychosom Med Psychol: 2010; 60 185 189
31. th, 2013
32. Levey A. S., Stevens L. A., Schmid C. H. et al. A new equation to estimate glomerular filtration rate. Ann Intern Med: 2009; 150 604 612
33. Humpert P. M., Papadopoulos G., Schaefer K. et al. sRAGE and esRAGE are not associated with peripheral or autonomic neuropathy in type 2 diabetes. Horm Metab Res: 2007; 39 899 902
34. von Eynatten M., Liu D., Hock C. et al. Urinary adiponectin excretion: a novel marker for vascular damage in type 2 diabetes. Diabetes: 2009; 58 2093 2099
35. Parving H. H., Lehnert H., Brochner-Mortensen J. et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med: 2001; 345 870 878
36. Goldstein D. S., Kopin I. J. Adrenomedullary, adrenocortical, and sympathoneural responses to stressors: a meta-analysis. Endocr Regul: 2008; 42 111 119
37. Cao J. J., Biggs M. L., Barzilay J. et al. Cardiovascular and mortality risk prediction and stratification using urinary albumin excretion in older adults ages 68-102: the Cardiovascular Health Study. Atherosclerosis: 2008; 197 806 813 (Pubitemid 351444791)
38. Gaede P., Lund-Andersen H., Parving H. H. et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med: 2008; 358 580 591 (Pubitemid 351214285)
39. Samann A., Pofahl S., Lehmann T. et al. Diabetic nephropathy but not HbA1c is predictive for frequent complications of Charcot feet - long-term follow-up of 164 consecutive patients with 195 acute Charcot feet. Exp Clin Endocrinol Diabetes: 2012; 120 335 339
40. de Groot E., Jukema J. W., Montauban van Swijndregt A. D. et al. B-mode ultrasound assessment of pravastatin treatment effect on carotid and femoral artery walls and its correlations with coronary arteriographic findings: a report of the Regression Growth Evaluation Statin Study (REGRESS). J Am Coll Cardiol: 1998; 31 1561 1567 (Pubitemid 28273299)
41. Crouse J. R. 3rd, Raichlen J. S., Riley W. A. et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA: 2007; 297 1344 1353 (Pubitemid 46513235)
42. Walton K. G., Schneider R. H., Nidich S. I. et al. Psychosocial stress and cardiovascular disease Part 2: effectiveness of the Transcendental Meditation program in treatment and prevention. Behav Med: 2002; 28 106 123 (Pubitemid 36603381)
43. Lin E. H., Rutter C. M., Katon W. et al. Depression and advanced complications of diabetes: a prospective cohort study. Diabetes Care: 2010; 33 264 269
44. van Son J., Nyklicek I., Pop V. J. et al. The effects of a mindfulness-based intervention on emotional distress, quality of life, and HbA(1c) in outpatients with diabetes (DiaMind): a randomized controlled trial. Diabetes Care: 2013; 36 823 830
45. Fujihara K., Saito A., Heianza Y. et al. Impact of psychological stress caused by the Great East Japan Earthquake on glycemic control in patients with diabetes. Exp Clin Endocrinol Diabetes: 2012; 120 560 563
46. Castillo-Richmond A., Schneider R. H., Alexander C. N. et al. Effects of stress reduction on carotid atherosclerosis in hypertensive African Americans. Stroke: 2000; 31 568 573 (Pubitemid 30131638)
47. Fields J. Z., Walton K. G., Schneider R. H. et al. Effect of a multimodality natural medicine program on carotid atherosclerosis in older subjects: a pilot trial of Maharishi Vedic Medicine. Am J Cardiol: 2002; 89 952 958 (Pubitemid 34310293)
48. Lowe B., Spitzer R. L., Grafe K. et al. Comparative validity of three screening questionnaires for DSM-IV depressive disorders and physicians' diagnoses. J Affect Disord: 2004; 78 131 140 (Pubitemid 38045472)
49. Rosenzweig S., Greeson J. M., Reibel D. K. et al. Mindfulness-based stress reduction for chronic pain conditions: variation in treatment outcomes and role of home meditation practice. J Psychosom Res: 2010; 68 29 36
50. Ward D. T., Alder A. C., Ohanian J. et al. Noradrenaline-induced paxillin phosphorylation, ERK activation and MEK-regulated contraction in intact rat mesenteric arteries. J Vasc Res: 2002; 39 1 11 (Pubitemid 34158354)
51. Hu Z. W., Shi X. Y., Lin R. Z. et al. alpha1-Adrenergic receptor stimulation of mitogenesis in human vascular smooth muscle cells: role of tyrosine protein kinases and calcium in activation of mitogen-activated protein kinase. J Pharmacol Exp Ther: 1999; 290 28 37 (Pubitemid 29302300)
52. Brand S., Holsboer-Trachsler E., Naranjo J. R. et al. Influence of mindfulness practice on cortisol and sleep in long-term and short-term meditators. Neuropsychobiology: 2012; 65 109 118
53. Rosenkranz M. A., Davidson R. J., Maccoon D. G. et al. A comparison of mindfulness-based stress reduction and an active control in modulation of neurogenic inflammation. Brain Behav Immun: 2013; 27 174 184.